<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BAT is a monoclonal antibody produced against membranes of Daudi cells that induces anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> activity in mice against a variety of solid murine and human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, mediated by its immune stimulatory properties on murine and human lymphocytes </plain></SENT>
<SENT sid="1" pm="."><plain>The present study analyzes the effect of BAT on <z:hpo ids='HP_0001909'>leukemia</z:hpo>/<z:hpo ids='HP_0002665'>lymphoma</z:hpo> using the BCL1 model of <z:hpo ids='HP_0001909'>leukemia</z:hpo>/<z:hpo ids='HP_0002665'>lymphoma</z:hpo> in BALB/C mice </plain></SENT>
<SENT sid="2" pm="."><plain>BAT antibody binds to BCL1 <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells and recognizes a 48 kDa protein similar to the antigen on Daudi cells </plain></SENT>
<SENT sid="3" pm="."><plain>Mice inoculated with <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells were treated either by direct BAT injections or by adoptive transfer of lymphocytes from BAT-injected mice </plain></SENT>
<SENT sid="4" pm="."><plain>Administration of BAT monoclonal antibody was either once, on day 14, or daily on days 10-13 post <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> inoculation </plain></SENT>
<SENT sid="5" pm="."><plain>A single injection of BAT resulted in reduction of peripheral blood <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells, however additional injections further decreased the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell number reaching a 95-fold reduction on day 20 post <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> inoculation </plain></SENT>
<SENT sid="6" pm="."><plain>Anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> effect was also obtained when animals were injected with splenocytes from BAT-treated donor mice </plain></SENT>
<SENT sid="7" pm="."><plain>A significant prolongation of survival of BAT-treated mice was observed although with no cure </plain></SENT>
<SENT sid="8" pm="."><plain>The results of this study indicate that BAT might be used for reducing the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden in <z:hpo ids='HP_0001909'>leukemia</z:hpo> for immunotherapy and in combination with other treatment modalities </plain></SENT>
</text></document>